Cats with idiopathic chronic rhinosinusitis that develop clinical signs before two years of age have more severe nasal conchal lysis, sinus malformation, and more severe inflammation on histological examination.

OBJECTIVE: To evaluate the severity of sinonasal lesions on CT in cats with feline idiopathic chronic rhinosinusitis (FICR) comparing cats who developed the condition at a young age to those who developed it as an adult. And, to assess if CT findings correlate with histopathology. ANIMALS: 58 cats with FICR confirmed on histopathology. METHODS: Medical records were retrospectively reviewed. Cats were divided into 2 groups based on their age category: juvenile (group 1, n = 30) and adult (group 2, 28), with juvenile cats being 2 years old or younger and adults being older than 2 years at the onset of clinical signs. Computed tomographic findings were recorded and graded (mild, moderate, and severe) by a board-certified radiologist, comparing each group. The CT findings were then compared to the histopathology results. RESULTS: The overall CT grade was not significantly different between the 2 groups (P = .21). Nasal conchal lysis was more severe in group 1 than in group 2 (P = .002), and group 1 also had a higher incidence of sinusal malformation (OR 2.42). Inflammatory infiltrates were more severe on histopathology in group 1 than in group 2 (OR 4.95), and the overall CT grade was slightly positively associated with the histological severity (κ = 0.2). CLINICAL RELEVANCE: Feline idiopathic chronic rhinosinusitis was associated with more severe nasal conchal lysis, sinus malformation, and more severe inflammation on histopathological examination in cats that develop clinical signs before 2 years of age. This finding could have an impact in term of clinical signs severity.

Blood biomarkers for canine cancer, from human to veterinary oncology.

In recent decades, interest in circulating tumour biomarkers is increasing both in human and veterinary oncology. An ideal tumour biomarker would allow early diagnosis of neoplasia, identify it specifically, accurately, establish a prognosis and predict its behaviour, especially regarding different therapeutic solutions. It would also allow to monitor its evolution over time and all this in a non-invasive and inexpensive way. Actually, no biomarkers meeting all of these criteria have been identified in veterinary medicine, particularly due to a lack of specificity of the main protein tumour biomarkers studied to date. However, great hope is currently placed in biomarkers grouped under the name of liquid biopsy, which could prove to be effective tools for common clinical use in the near future. This review gives an update on blood cancer biomarkers studied in dogs, such as ions, proteins, nucleic acids and also circulating cells, of which some might become more prominent in the coming years to help improve the management of animal care.